VectivBio Holding AG (VECT) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

VectivBio Holding AG (VECT) Healthcare & Pipeline Overview

VectivBio Holding AG, a clinical-stage biopharmaceutical firm, specializes in rare disease therapeutics, with apraglutide undergoing Phase III trials for short bowel syndrome-intestinal failure (SBS-IF). Their focus on unmet needs and a promising pipeline positions them in the competitive biotech landscape, despite current unprofitability.

What Is the Investment Thesis for VECT?

VectivBio presents a high-risk, high-reward investment opportunity centered on the potential success of apraglutide. The Phase III trial for SBS-IF is a critical value driver; positive results and subsequent FDA/EMA approval could lead to significant revenue generation. The ongoing Phase II trials for other indications like aGvHD provide further upside potential. However, the company's current negative profit margin of -342.8% and lack of revenue necessitate careful monitoring of cash burn and future financing needs. The company's market capitalization of $1.06B reflects investor optimism regarding apraglutide's prospects, but this valuation is sensitive to clinical trial outcomes and regulatory decisions. Investors should closely track trial data releases and regulatory updates to assess the risk-reward profile.

Based on FMP financials and quantitative analysis

VECT Key Highlights

• Market Cap of $1.06B reflects investor expectations for apraglutide's success in treating rare gastrointestinal disorders.
• Gross Margin of 100.0% indicates strong potential profitability upon commercialization, though currently offset by high R&D expenses.
• Phase III clinical trial for apraglutide in SBS-IF represents a key milestone with potential for significant value creation.
• Negative Profit Margin of -342.8% highlights the company's current reliance on funding and the inherent risks of clinical-stage biopharmaceutical companies.
• Beta of 0.10 suggests the stock is less volatile than the overall market, potentially due to its focus on a specific therapeutic area.

Who Are VECT's Competitors?

VECT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VECT's Key Strengths?

• Promising lead product candidate, apraglutide, in Phase III clinical trials.
• Focus on rare diseases with high unmet medical needs.
• Experienced management team with expertise in drug development.
• Strong intellectual property protection for its drug candidates.

What Are VECT's Weaknesses?

• Currently unprofitable with a high operating loss.
• Reliance on the success of a single drug candidate, apraglutide.
• Limited commercial infrastructure.
• Dependence on external funding to finance operations.

What Could Drive VECT Stock Higher?

• Data readout from Phase III clinical trial of apraglutide for SBS-IF expected in late 2026.
• Potential FDA/EMA approval of apraglutide for SBS-IF in 2027, contingent on positive Phase III results.
• Enrollment and progress in Phase II clinical trials of apraglutide for SBS-IF with colon-in-continuity and aGvHD.

What Are the Key Risks for VECT?

• Negative return on equity (-56.9%) — the business is not currently generating profit on shareholder capital.
• Failure to achieve positive results in Phase III clinical trial of apraglutide for SBS-IF.
• Regulatory delays or rejection of apraglutide's marketing application.
• Competition from other companies developing therapies for rare gastrointestinal disorders.
• Dependence on external funding to finance operations and clinical development programs.
• Difficulty in recruiting patients for clinical trials.

What Are the Growth Opportunities for VECT?

• Apraglutide for SBS-IF: The primary growth driver is the successful completion and commercialization of apraglutide for short bowel syndrome-intestinal failure (SBS-IF). The SBS-IF market is estimated to be substantial, with a significant unmet need for effective therapies. Positive Phase III results, expected in late 2026, could lead to regulatory approval and rapid market penetration, establishing apraglutide as a leading treatment option. VectivBio's competitive advantage lies in apraglutide's long-acting formulation, potentially offering improved patient convenience and adherence.
• Apraglutide for SBS-IF with Colon-in-Continuity: Expanding the indication of apraglutide to include SBS-IF patients with colon-in-continuity represents another growth opportunity. The Phase II trial is ongoing, and positive results could broaden the addressable patient population. This expansion would solidify apraglutide's position in the SBS-IF market and increase its revenue potential. The timeline for commercialization depends on the Phase II trial outcome and subsequent regulatory filings, potentially reaching the market by 2028.
• Apraglutide for Steroid-Refractory aGvHD: Developing apraglutide for steroid-refractory gastrointestinal acute versus host disease (aGvHD) offers a significant growth opportunity. The Phase II trial is underway, and positive data could lead to a new treatment option for this challenging condition. The aGvHD market is characterized by limited treatment options and a high unmet need. Successful development and commercialization of apraglutide for aGvHD could generate substantial revenue. Market entry is projected for 2029, pending successful trial outcomes and regulatory approvals.
• Geographic Expansion: Expanding commercial operations beyond the initial target markets of the United States and Europe represents a long-term growth opportunity. Entering new geographic regions, such as Asia-Pacific and Latin America, could significantly increase the addressable patient population for apraglutide. This expansion would require strategic partnerships and regulatory approvals in each new market. The timeline for geographic expansion is dependent on the success of apraglutide in the initial markets and the availability of resources.
• Pipeline Expansion: VectivBio can leverage its expertise in rare gastrointestinal disorders to expand its pipeline with new drug candidates. Identifying and developing novel therapies for other rare conditions could diversify the company's revenue streams and reduce its reliance on apraglutide. This expansion would involve research and development efforts, as well as potential acquisitions or licensing agreements. The timeline for pipeline expansion is uncertain and depends on the availability of promising drug candidates.

What Opportunities Does VECT Have?

• Successful completion of clinical trials and regulatory approval for apraglutide.
• Expansion of apraglutide's indications to other rare gastrointestinal disorders.
• Strategic partnerships with larger pharmaceutical companies.
• Acquisition of complementary technologies or drug candidates.

What Threats Does VECT Face?

• Clinical trial failures or delays.
• Regulatory setbacks or rejection of drug applications.
• Competition from other companies developing therapies for rare diseases.
• Changes in healthcare regulations or reimbursement policies.

What Are VECT's Competitive Advantages?

• Patent protection for apraglutide provides market exclusivity.
• Orphan drug designation offers regulatory advantages and market exclusivity.
• Specialized expertise in developing therapies for rare gastrointestinal disorders.
• Strong relationships with key opinion leaders in gastroenterology.

What Does VECT Do?

VectivBio Holding AG, incorporated in 2019 and headquartered in Basel, Switzerland, is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines for severe rare conditions. The company's primary focus is on addressing unmet medical needs in gastrointestinal disorders. Their lead product candidate, apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 (GLP-2), is currently in Phase III clinical development for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF). Apraglutide is also in Phase II clinical trials for SBS-IF in patients with colon-in-continuity anatomy and for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio aims to improve the lives of patients suffering from rare and debilitating conditions through targeted therapies. The company's strategic approach involves rigorous clinical trials and a commitment to bringing novel treatments to market. VectivBio operates primarily in the biotechnology sector, focusing on rare diseases with significant unmet medical needs. Their pipeline is centered around apraglutide, with potential expansion into other rare gastrointestinal disorders. The company's success hinges on the successful completion of clinical trials and subsequent regulatory approvals.

What Products and Services Does VECT Offer?

• Develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 (GLP-2).
• Conducts Phase III clinical trials for apraglutide in the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF).
• Conducts Phase II clinical trials for apraglutide in SBS-IF patients with colon-in-continuity anatomy.
• Conducts Phase II clinical trials for apraglutide in patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD).
• Focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions.
• Aims to address unmet medical needs in gastrointestinal disorders through targeted therapies.

How Does VECT Make Money?

• Develops and patents novel therapeutic drugs for rare diseases.
• Conducts clinical trials to demonstrate the safety and efficacy of its drug candidates.
• Seeks regulatory approval from agencies like the FDA and EMA to market its drugs.
• Commercializes approved drugs through its own sales force or partnerships.

What Industry Does VECT Operate In?

VectivBio operates within the competitive biotechnology industry, specifically targeting rare diseases. The market for rare disease treatments is growing, driven by increased awareness, regulatory incentives, and advancements in drug development technologies. Companies like Albireo Pharma (ALBO), Cymabay Therapeutics (CBIO), and Chimerix (CMRX) are also focused on developing therapies for rare diseases, creating a competitive landscape. VectivBio's success depends on its ability to differentiate apraglutide through superior efficacy, safety, and patient outcomes. The regulatory pathway for rare disease drugs often involves orphan drug designation, which provides market exclusivity and other benefits.

Who Are VECT's Key Customers?

• Patients suffering from short bowel syndrome-intestinal failure (SBS-IF).
• Patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD).
• Healthcare providers who treat patients with rare gastrointestinal disorders.
• Hospitals and clinics that specialize in gastroenterology.

Company Profile

VectivBio Holding AG operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Basel, CH. The company is led by CEO Luca Santarelli. VECT has traded publicly since 2021.

How VectivBio Holding AG Is Valued

VectivBio Holding AG carries a market capitalization of $1.06B, placing it in the small-cap category. Relative to its peer group, VECT's quantitative score of 59/100 is roughly in line with the peer average of 59/100.

ROE -57%Key Financial Metrics

Return on equity for VectivBio Holding AG stands at -56.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -37.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.14 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.6%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 4/9Financial Health

VectivBio Holding AG's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 13.93 places it in the safe zone, indicating low near-term bankruptcy risk.

VECT Financials

VECT Latest News

VECT Analyst Consensus

VECT MoonshotScore

VECT Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources